BPC-157 10mg
In Stock & Ready to Ship from USA
FREE shipping on orders over $200
Secure checkout via encrypted payment processor
+2.9kResearch Use Only
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Summary
30 PubMed CitationsOverview BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2] Originally isolated by Dr. Predrag Sikiric's research group at the University of Zagreb in 1993, BPC-157 is one of the most extensively studied cytoprotective peptides in preclinical literature. It demonstrates pleiotropic effects across gastrointestinal, musculoskeletal, neurological, and vascular models.[8] A key distinguishing feature is its exceptional stability — BPC-157 resists enzymatic degradation in human gastric juice for over 24 hours, is effective via multiple routes (oral, parenteral, topical) without requiring a carrier molecule, and has shown no lethal dose (LD1) in toxicology studies.[3][9] The U.S. FDA placed BPC-157 on the Category 2 Bulk Drug Substances list in September 2023, citing potential immunogenicity risks and insufficient safety data for human compounding.[4] WADA explicitly banned BPC-157...
BPC-157 10mg at a glance
| Specification | Detail |
|---|---|
| Format | Lyophilized powder, 10mg per vial |
| Purity specification | ≥99%, by reversed-phase HPLC |
| Third-party testing | HPLC purity report published on this page as a downloadable PDF — no account or order required to open it. Batch-specific documentation available on request. |
| Price | $65.00 per 10mg vial |
| Price per mg | $6.50 per mg |
| Dispatch | Same business day on orders placed before 2:00 PM EST, Monday-Friday |
| U.S. delivery time | USPS Priority Mail 2-3 business days; UPS Ground 3-5 business days |
| Shipping cost | Free on U.S. orders over $200 |
| Ships to | All 50 U.S. states. No international shipping. |
| Packaging | Discreet, unbranded outer packaging; tracking number emailed at dispatch |
| Storage | Lyophilized: -20°C, protected from light. Reconstituted: 2-8°C, avoiding freeze-thaw cycles. |
| Regulatory status | Not an FDA-approved drug. Listed by the FDA as a Category 2 bulk drug substance (September 2023) and prohibited by WADA under category S0 (effective January 1, 2022). |
| Intended use | Research use only — not for human, veterinary, diagnostic, or therapeutic use. |
Price and availability reflect the live product record; the purchase panel at the top of this page is the source of truth.
How to evaluate a BPC-157 vendor
Worth checking before buying BPC-157 from any supplier, and how this listing answers each point. These are our own verifiable facts — we make no claims about other sellers.
| What to check | How this listing answers it |
|---|---|
| Is a purity report actually published, or only described? | The BPC-157 HPLC purity report is published on this page as a downloadable PDF. A purity figure described in body copy is not the same as a report you can open. |
| Does the report name the analytical method? | Reversed-phase HPLC for purity, with mass spectrometry for identity confirmation. It is always worth asking which method produced a stated number. |
| Can documentation be tied to the batch received? | Batch-specific documentation is available on request from lab support against an order number. |
| Where does it ship from, and where can it go? | Dispatched from a U.S. facility to all 50 U.S. states. No international shipping. |
| How quickly does an order actually leave? | Same-business-day dispatch before 2:00 PM EST Monday-Friday, then 2-3 business days by USPS Priority Mail or 3-5 by UPS Ground, with tracking emailed at dispatch. |
| What is the real cost per milligram? | $6.50 per mg, at the current listed price of $65.00 per 10mg vial. Comparing vial prices across different vial sizes is misleading — compare price per mg. |
| Is regulatory status disclosed or buried? | Stated plainly on this page: FDA Category 2 bulk drug substances list (September 2023) and WADA S0 prohibition (January 1, 2022). Supplied for laboratory research use only. |
| Is the compound backed by literature you can check? | 30 references with DOI or PubMed links are listed in the Referenced Citations section of this page. |
BPC-157 — Research Data at a Glance
| Property | Value |
|---|---|
| PubMed Citations Referenced | 30 |
| Contributing Researchers | 3 |
| Storage Conditions | BPC-157 is uniquely stable at room temperature. |
| Purity Standard | ≥99% (HPLC verified, 3rd-party COA) |
| Research Use Only | Not for human consumption. RUO only. |
Compare BPC-157 with Other Peptides
Research guide
What is BPC-157? Read the full research guideOverview
Overview
BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2]
Originally isolated by Dr. Predrag Sikiric's research group at the University of Zagreb in 1993, BPC-157 is one of the most extensively studied cytoprotective peptides in preclinical literature. It demonstrates pleiotropic effects across gastrointestinal, musculoskeletal, neurological, and vascular models.[8]
A key distinguishing feature is its exceptional stability — BPC-157 resists enzymatic degradation in human gastric juice for over 24 hours, is effective via multiple routes (oral, parenteral, topical) without requiring a carrier molecule, and has shown no lethal dose (LD1) in toxicology studies.[3][9]
The U.S. FDA placed BPC-157 on the Category 2 Bulk Drug Substances list in September 2023, citing potential immunogenicity risks and insufficient safety data for human compounding.[4] WADA explicitly banned BPC-157 under S0 (Non-approved Substances) effective January 1, 2022.[5]
Discovery and structural rationale
The "Body Protection Compound" parent protein was identified during investigations of organoprotective constituents of mammalian gastric juice in the late 1980s. The 15-residue active fragment GEPPPGKPADDAGLV preserves the proline-rich motif now believed to be central to its bioactivity: computational modeling reported in a non-peer-reviewed 2025 preprint proposes that the peptide adopts a polyproline II (PPII) helix in solution, a class of conformation recognized by the SH3 domains of Src-family kinases.[11] This proposed conformational basis, if confirmed experimentally, would distinguish BPC-157 from the disulfide- or alpha-helix-stabilized peptides typical of the regulatory-peptide literature.[1]
Research framework
Within the cytoprotective-peptide research domain, BPC-157 is most often referenced alongside Thymosin alpha-1 for parallel tissue-repair signaling, TB-500 for actin-cytoskeleton-mediated wound dynamics, and GHK-Cu for matrix-remodeling pathways. The compound is supplied here strictly as a reference standard for in vitro and animal-model investigation, and is not intended for human or veterinary use.
Mechanism of Action
Mechanism of Action
VEGFR2 Activation (Primary Target)
BPC-157 binds to and activates vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells. Unlike standard ligands, BPC-157 promotes VEGFR2 internalization — a critical step in activating downstream repair pathways.[7]
Src Family Kinase Activation
A 2025 preprint, posted to Research Square and not yet peer-reviewed, combines in-silico docking and structural modeling with a fluorescent fusion-protein construct to propose that BPC-157 adopts a polyproline II helix capable of engaging the SH3 domains of Src family kinases (c-Src, Yes, Fyn), which the author suggests would relieve autoinhibition and act as an intracellular "switch" for signal transduction. This is a computational hypothesis; the binding has not been demonstrated by experimental structure determination.[11]
VEGFR2-Akt-eNOS Cascade
Upon VEGFR2 binding, BPC-157 triggers phosphorylation of Akt (Protein Kinase B), which activates endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO) — essential for angiogenesis and vascular repair.[7]
Src-Caveolin-1-eNOS Pathway
BPC-157 promotes phosphorylation of Src and Caveolin-1 (Cav-1). Under normal conditions, Cav-1 inhibits eNOS — BPC-157 disrupts this inhibitory complex, enhancing NO production.[7]
FAK-Paxillin Pathway
In tendon fibroblasts, BPC-157 activates focal adhesion kinase (FAK) and paxillin, essential for cell migration, adhesion, and cytoskeletal organization during tissue repair.[12]
JAK-2 / Growth Hormone Receptor Upregulation
BPC-157 activates JAK-2, linked to upregulation of growth hormone receptors (GHR) on tendon fibroblasts, enhancing tissue sensitivity to growth hormone.[12][13]
Egr-1/NAB2 Feedback Loop
ERK1/2 activation upregulates Egr-1 and simultaneously its corepressor NAB2, establishing a feedback loop that prevents uncontrolled angiogenic signaling.[14]
Nitric Oxide System Modulation (Bidirectional)
BPC-157 exhibits a unique modulatory interaction with the NO system — it counteracts both L-NAME (NOS inhibitor → hypertension) and L-arginine (NOS substrate → hypotension), acting as a homeostatic buffer rather than a strict agonist or antagonist.[15]
Dopamine/Serotonin System Regulation
BPC-157 antagonizes the effects of dopamine receptor blockers (haloperidol) and agonists (amphetamine), as well as serotonin syndrome precursors — suggesting a regulatory influence on these neurotransmitter systems rather than direct receptor binding.[16]
Egr-1/NAB2 Angiogenic Restraint Loop
The Egr-1/NAB2 motif investigated in BPC-157 work distinguishes it from unrestrained pro-angiogenic ligands such as exogenous VEGF-A. By co-inducing the corepressor NAB2, BPC-157-stimulated angiogenesis remains negatively regulated by an intrinsic feedback element, which preclinical authors have proposed as one explanation for the compound's broad therapeutic-index profile in animal models.[14][29]
Brain-Gut Axis Crosstalk
Sikiric and colleagues have positioned BPC-157 as an integrator of the brain-gut axis, with effects observed in both peripheral mucosal injury and central nervous system models reflecting parallel cytoprotective signaling. This cross-axis activity is hypothesized to involve coordinated VEGFR2/eNOS and dopamine/serotonin tone normalization, supporting a single underlying organoprotective mechanism rather than tissue-specific receptor families.[2][3]
Research Applications
Research Applications
BPC-157 demonstrates pleiotropic effects across multiple experimental paradigms, with unusually broad tissue coverage for a single peptide:
- Gastrointestinal Healing — Anti-ulcer peptidergic agent effective against IBD, ulcerative colitis, NSAID-induced lesions, and complex fistulas. Phase II human data available (n=53, ulcerative colitis).[6]
- Musculoskeletal Regeneration — Accelerated healing of transected/detached tendons (Achilles, quadriceps), ligaments (MCL), and skeletal muscle injuries. Improved biomechanical function and reversed corticosteroid impairment.[17][18]
- Neuroprotection and CNS Repair — Protective in models of TBI, spinal cord compression, and bilateral carotid occlusion. Reduced edema, neuronal necrosis, demyelination. Functional recovery maintained to 1 year (spinal cord).[19][20]
- Vascular Occlusion Models — Rapidly activates collateral vessels to bypass occlusions (Budd-Chiari syndrome, Pringle maneuver). Prevents thrombotic/ischemic damage and preserves organ function.[21]
- Corneal Healing — Maintains corneal transparency and accelerates ulcer/perforation healing without inducing neovascularization (uniquely anti-angiogenic in cornea).[22]
- Hepatoprotection — Protective against alcohol/NSAID-induced liver injury, fibrosis, and cirrhosis. Normalized liver enzymes and bilirubin in bile duct ligation models.[23]
- Pain Management — Human pilot data: intra-articular injection (2 mg) for knee pain (91.6% significant improvement, n=16) and intravesical injection (10 mg) for interstitial cystitis (83.3% complete resolution, n=12).[24][25]
- Dopaminergic/Serotonergic Modulation — Efficacy in models of schizophrenia and depression; counteracted catalepsy, amphetamine-induced hyperactivity, and ketamine-induced "negative-like" symptoms.[16]
- Bidirectional NO-System Modulation Studies — Investigated for its capacity to counteract both NOS inhibition (L-NAME) and NOS-substrate excess (L-arginine), positioning it in research as a homeostatic NO buffer rather than a unidirectional agonist or antagonist.[15]
- Polyproline-Helix / SH3 Engagement Profiling — Examined for the conformational basis of its broad signaling profile, with computational modeling in a non-peer-reviewed preprint hypothesizing that Src-family-kinase SH3 engagement could underlie the diverse downstream phosphorylation cascades reported across organ systems.[11]
Comparative Research Context
BPC-157 is most commonly cross-referenced in the cytoprotection literature with TB-500 (actin-mediated repair), GHK-Cu (matrix remodeling), and Thymosin alpha-1 (immunoregulation). These cross-comparisons inform research designs investigating whether BPC-157's pleiotropic profile reflects a single integrative kinase-engagement mechanism or convergent activity across independent reparative pathways.[29][30]
Biochemical Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1419.556 g/mol |
| CAS Number | 137525-51-0 |
| Sequence (3-Letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Sequence (1-Letter) | GEPPPGKPADDAGLV |
| Amino Acids | 15 (linear pentadecapeptide) |
| Structural Type | Linear pentadecapeptide, no disulfide bridges; a polyproline II helix is proposed by computational modeling, not experimentally determined |
| Parent Molecule | Body Protection Compound (BPC) from human gastric juice |
| Synonyms | Bepecin, PL 14736, PL-10, PLD-116, PCO-02 |
| Plasma Half-Life | <30 minutes (IV/IM) |
Identifiers
| PubChem CID | |
|---|---|
| InChI Key | |
| Isomeric SMILES | |
| Drug Codes |
Preclinical Research Summary
Preclinical Research Summary
Key Preclinical Studies
| Study | Model | Key Findings | Ref |
|---|---|---|---|
| He et al. (2022) | SD rats / Beagle dogs | PK study: IV t½ = 15.2 min (rats), 5.27 min (dogs); bioavailability 14-19% (rats IM), 45-51% (dogs IM); distributed to kidney, liver, stomach | [26] |
| Xu et al. (2020) | Mice, rats, rabbits, dogs | Multi-species toxicity: no LD1 achieved, no adverse signs at 20 mg/kg (rats) or 10 mg/kg (dogs) | [9] |
| Staresinic et al. (2003) | Rats — Achilles transection | 10 µg/kg IP: improved AFI scores, increased load-to-failure at 14-72 days; reversed corticosteroid impairment | [17] |
| Tudor et al. (2010) | Mice — TBI | 10 µg/kg IP: reduced brain edema, hemorrhage, and mortality; improved conscious/unconscious/death ratio | [19] |
| Perovic et al. (2019) | Rats — spinal cord | 200 µg/kg IP: axonal recovery maintained to 1 year; counteracted necrosis, demyelination, cyst formation | [20] |
| Vukojevic et al. (2020) | Rats — bilateral carotid occlusion | Upregulated Egr1/Akt1/Src/Vegfr2/Nos3; downregulated Nos2/Nfkb in hippocampus | [14] |
| Hsieh et al. (2017/2020) | Rat hind limb ischemia + CAM | 129–152% increased angiogenesis; VEGFR2-Akt-eNOS pathway confirmed | [7] |
| Sever et al. (2019) | Rats — bile duct ligation | Reversed liver fibrosis, cirrhosis, and portal hypertension; normalized enzymes/bilirubin | [23] |
| Matek et al. (2025) | Rats — quadriceps detachment | Oral BPC-157 in drinking water: full muscle-to-bone reattachment at 90 days; annihilated leg contracture | [18] |
| Chang et al. (2011/2014) | Rat tendon fibroblasts (in vitro) | ↑ GHR expression, activated FAK-paxillin pathway, enhanced cell survival and migration | [12][13] |
Clinical / Human Studies
| Study | Design | n= | Key Outcome | Ref |
|---|---|---|---|---|
| Phase II Ulcerative Colitis | Multicenter RCT, double-blind, placebo-controlled | 53 | 80 mg enema daily × 2 wks: significant DAI decrease vs placebo; very well-tolerated, no AEs vs placebo | [6] |
| Phase I PK/Safety | Single-blind, placebo-controlled | 32 | Rectal 0.25-2 mg/kg: very low systemic absorption; well-tolerated, no safety differences vs placebo | [27] |
| Knee Pain Retrospective | Chart review | 16 | 2 mg intra-articular: 91.6% significant improvement lasting 6 months–1 year; no adverse effects | [24] |
| Interstitial Cystitis Pilot | Pilot study | 12 | 10 mg intravesical: 83.3% complete resolution, remaining 2 subjects reported 80% improvement; no AEs | [25] |
| IV Safety Pilot | Pilot study | 2 | 10-20 mg IV: no adverse effects on cardiac, hepatic, renal, or thyroid biomarkers | [28] |
Pharmacokinetic Parameters
| Parameter | Value | Ref |
|---|---|---|
| IV Half-life (rats) | 15.2 minutes | [26] |
| IV Half-life (dogs) | 5.27 minutes | [26] |
| Bioavailability IM (rats) | 14–19% | [26] |
| Bioavailability IM (dogs) | 45–51% | [26] |
| Tmax (rats) | ~3 minutes | [26] |
| Major Metabolite | Proline (amino acid) | [26] |
| Gastric Stability | >24 hours in human gastric juice | [3] |
| Urine Detection | 4–5 days via LC-MS | [26] |
| Lethal Dose | Not achieved (>2 g/kg IV/IG in mice) | [9] |
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
Authors & Attribution
✍️ Article Author
Dr. Predrag Sikiric
Predrag Sikiric, MD, PhD, is a Professor at the Department of Pharmacology, School of Medicine, University of Zagreb, Croatia. Dr. Sikiric is the lead researcher who originally isolated BPC-157 from human gastric juice in 1993. He is responsible for the vast majority of the existing literature (over 80% of published studies) on the peptide. His work established the cytoprotection/organoprotection framework, demonstrating BPC-157's pleiotropic effects on organ healing (stomach, liver, muscle, tendon, nerve), the nitric oxide system, and the brain-gut axis. Predrag Sikiric is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →🎓 Scientific Journal Author
Dr. Sven Seiwerth
Sven Seiwerth, MD, PhD, is affiliated with the Department of Pathology, School of Medicine, University of Zagreb, Croatia. A long-time collaborator with Dr. Sikiric, Dr. Seiwerth focuses on the pathology and histological aspects of BPC-157's healing effects. His research specifically highlights the peptide's role in wound healing, angiogenesis, and tissue repair in tendons, ligaments, and muscles. He has co-authored numerous key reviews including landmark papers on BPC-157 and angiogenic growth factors (2018), wound healing (2021), and blood vessel effects (2014). Sven Seiwerth is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →Dr. Sven Seiwerth is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
🔬 Contributing Researcher
Dr. Chung-Hsun Chang
Chung-Hsun Chang, PhD, is affiliated with the Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taiwan. Dr. Chang leads an independent research group that has provided critical insight into the molecular mechanisms of BPC-157 in connective tissue. His work demonstrated that BPC-157 enhances the expression of growth hormone receptors in tendon fibroblasts and activates the FAK-paxillin pathway, promoting cell migration and repair. This research is frequently cited as independent (non-Zagreb) confirmation of BPC-157's effects on soft tissue healing. Chung-Hsun Chang is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →Dr. Chung-Hsun Chang is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
Referenced Citations
Sikiric P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology-Paris. 1993;87(5):313-327.
DOISikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
DOISikiric P, Hahm KB, Blagaic AB, Tvrdeic A, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167.
DOIU.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA.gov. Updated 2023.
FDA.govWorld Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025.
WADARuenzi M, et al. BPC-157 in patients with ulcerative colitis: A Phase II multicenter, randomized, double-blind, placebo-controlled study. Gastroenterology. 2005;128(Suppl 2):A-585.
PubMedHsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333.
DOISikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals (Basel). 2025;18(6):928.
PubMedXu C, et al. Preclinical safety evaluation of body protection compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665.
DOIChang CH, Tsai WC, Hsu YH, Pang JS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
DOISchlosser SK. BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production. Research Square. 2025. Preprint, not peer-reviewed.
DOIChang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
DOIChang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077.
DOIVukojević J, Siroglavić M, Kašnik K, Kralj T, et al. Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascular Pharmacology. 2018;106:54-66.
DOISikiric P, et al. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. 1999;7(1):1-14.
DOIZemba Cilic A, Zemba M, Cilic M, Balenovic I, Strbe S, et al. Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. Behavioural Brain Research. 2021;396:112919.
DOIStaresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983.
DOIMatek D, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119.
PubMedTudor M, et al. The gastroprotective and neuroprotective pentadecapeptide BPC 157 in the treatment of traumatic brain injury in rats. Regulatory Peptides. 2010;160(1-3):26-32.
DOIPerovic D, Kolenc D, Bilic V, Somun N, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research. 2019;14(1):199.
DOISikiric P, et al. Vascular occlusion and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2022;28(25):2082-2093.
PubMedMasnec S, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Experimental Eye Research. 2015;136:9-15.
PubMedSever M, et al. Stable gastric pentadecapeptide BPC 157 counteracts liver fibrosis. Journal of Physiology and Pharmacology. 2019;70(3):391-400.
PubMedLee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13.
PubMedLee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12-17.
PubMedHe L, Feng D, Guo H, Zhou Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182.
DOIVeljaca M, et al. BPC-157: Safety and pharmacokinetics after rectal administration in healthy male volunteers. Gut. 2003;52(Suppl VI):A246.
PubMedLee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24.
PubMedSeiwerth S, Rucman R, Turkovic B, Sever M, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. 2018;24(18):1972-1989.
DOISeiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533.
DOIRUO Disclaimer
For Research Use Only (RUO). Not intended for human consumption, clinical use, or as a drug, food, cosmetic, or medical device. This product has not been evaluated by the FDA and is supplied solely for in-vitro laboratory research by qualified professionals.
Certificate of Analysis
Each lot is independently tested by accredited third-party laboratories (ISO 17025) at 99%+ purity.
Latest Lab Report
Storage & Handling
Summary
BPC-157 is uniquely stable at room temperature. Standard recommendation: -20°C for long-term storage; reconstituted solutions at 2-8°C.
Recommended Laboratory Storage Conditions
Lyophilized Powder: BPC-157 is noted for being stable at room temperature — a distinct advantage over most thermolabile peptides. However, standard recommendation is -20°C (-4°F) for long-term storage to maximize shelf life.
Gastric Stability: Highly resistant to hydrolysis and enzymatic degradation in human gastric juice, remaining stable for >24 hours.
Reconstituted Solution: Refrigerate at 2–8°C (36–46°F). Use standard peptide handling protocols: reconstitute with bacteriostatic water or sterile saline.
Handling: Allow vial to reach room temperature before opening. Standard aseptic technique for all preparations. Discard any solution that appears cloudy or contains particulate matter.
“Preclinical Research Summary Key Preclinical Studies Study Model Key Findings Ref He et al.”
Frequently Asked Questions
Common research questions about BPC-157 — purity, handling, COA documentation, and published-research context.
Related Research Compounds
BPC-157 20mg + TB-500 20mg Bundle
BPC-157 10mg + TB-500 10mg Bundle
VIP
10mg